Precise. Personalized. Predictive.
Venebio Opioid Advisor Clinical Decision Support
Over the last two decades, prescription opioid-related overdose and deaths from opioid-induced respiratory depression (OIRD) have emerged as a major public health threat in the United States. Overdose deaths involving prescription opioids have quadrupled since 1999 and parallel the striking increase of U.S. sales and consumption of prescription opioids. From 1999 to 2015, more than 183,000 people have died in the U.S. from overdoses related to prescription opioids.
More about the opioid overdose epidemic.
In response to the public health threat posed by the opioid overdose epidemic, Venebio Group developed the Venebio Opioid Advisor (VOA) clinical decision support tool to support safer opioid prescribing.
The tool provides an evidence-based, quantitative estimate of a patient’s likelihood of experiencing a life-threatening opioid emergency in the next six months. It characterizes the patient’s specific risk factor profile and provides individualized, evidence-based, risk-mitigation interventions for the health care professional and patient.
More about Venebio Opioid Advisor.
The development of VOA built on our previously published predictive models and scoring systems that estimate the level of risk of experiencing an adverse outcome.
VOA has undergone extensive retrospective validation, initially in a case-control study of U.S. military veterans, followed by validation in a more representative population using the IMS PharMetrics Plus™ database of 18+ million prescription opioid users.
Implementing VOA can prevent more than 500 overdoses per 100,000 opioid recipients per year. This translates into preventing over 400 prescription opioid overdose-related emergency department visits, avoiding over 120 hospitalizations, and reducing annual health care costs by $2 million per 100,000 patients receiving opioid therapy.
More about our research.
Although the adoption of PDMPs is an effort that holds promise, their ability to stem opioid overprescribing is inherently limited by the specific form of misuse that the programs aim to address. Read more in this insightful Brookings Op-Ed here.
The devastation of the nation’s opioid epidemic does not need further explanation. Seemingly every day, news stories underscore the fact that opioid overdose knows no gender, race or class boundaries. Too few of these stories, however, speak of available solutions to combat this epidemic. Read the full article by Mark […]
Venebio’s Chief Medical Officer, Barb Zedler, M.D., penned an opinion piece in response to an interim report from President Trump’s Commission on Combating Drug Addiction and the Opioid Crisis, which was published in the Philadelphia Inquirer. Read the piece here.
Venebio Opioid Advisor and Venebio’s efforts to address the opioid overdose epidemic were featured in Virginia Business magazine. Read the article here.
Venebio Group will present at the upcoming Health 2.0 Annual Fall Conference in Santa Clara, CA on October 2, 2017. During the presentation, Mr. Mark Tripodi, Venebio’s Chief Development Officer, will highlight the Venebio Opioid Advisor clinical decision support tool and its benefits toward safer opioid prescribing.
RICHMOND, Va. (September 22, 2017) – Venebio Group, a leader in personalized risk prediction algorithms, today announced that Amida Care, a New York-based health plan provider, has implemented Venebio Opioid Advisor™ (VOA™), the company’s risk-screening tool for prescription opioid overdose. Amida Care is the second health plan to use VOA following […]